Nordic pharma manufacturer scaling R&D in oncology and pain with AI-driven discovery tools
Orion Pharma is a publicly traded Nordic pharmaceutical manufacturer with ~4,000 employees across R&D, manufacturing, and regulatory operations. The tech stack reveals a transition toward AI-assisted drug discovery: AlphaFold adoption pairs with Unity Catalog infrastructure, signaling investment in computational biology workflows and data governance. Active hiring across research, manufacturing, and regulatory roles—with specialized positions like Structural Biology Lead—aligns with their core R&D focus on oncology and pain therapies.
Notable leadership hires: Structural Biology Lead, Occupational Health Head
Orion Pharma develops, manufactures, and markets human and veterinary pharmaceuticals, along with active pharmaceutical ingredients (APIs) and consumer health products. The company operates across three main pillars: proprietary medicines (oncology, pain, respiratory, neurological), generic medicines, and consumer health. With headquarters in Espoo, Finland, and operations across 14 countries, they serve mid-market and enterprise healthcare buyers. Current challenges center on regulatory complexity (product-launch delays, variation submissions, nonclinical studies), manufacturing reliability, and data governance compliance.
Core platforms: SAP, Databricks, Azure (Data Lake, Synapse), AWS, GCP. Recently adopting AlphaFold and Unity Catalog for drug discovery and data governance. Also use Dynamics 365, Fiori, and Microsoft 365 suite.
Core therapy areas are oncology and pain. Proprietary portfolio also includes respiratory and neurological disease treatments. Current projects include ligand assay integration, nonclinical safety studies, and manufacturing line transfers.
Other companies in the same industry, closest in size